Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series.

Background: Faricimab is a novel anti-vascular endothelial growth factor agent, used to treat patients with neovascular age-related macular degeneration (nAMD). This study assessed efficacy and safety of faricimab in previously treated eyes.

Methods: This retrospective study included previously treated nAMD patients who had received at least three faricimab injections.